Through its partnership with the US-based biotech Aptevo Therapeutics, Alligator Bioscience is evaluating the bispecific antibody ALG.APV-527 for the treatment of solid tumours in a phase I dose-escalation trial. The companies have announced positive interim results from the dose escalation part of the study, and BioStock spoke with Alligator's CEO Søren Bregenholt to learn more.

Read the article at biostock.se:

Clinical effects observed with Alligator's 4-1BB agonist - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/alligator-bioscience/r/biostock--clinical-effects-observed-with-alligator-s-4-1bb-agonist,c3945791

(c) 2024 Cision. All rights reserved., source Press Releases - English